Search Results (133)

To address the lack of a commercially available vaccine for goose circovirus (GoCV), we developed and evaluated a prokaryotically expressed subunit vaccine targeting the viral capsid (Cap) protein. A truncated Cap protein (GoCV-ΔCap) was expressed in Escherichia coli (E. coli) and formulated with aluminum hydroxide as a subunit vaccine (GoCVsubvac). Goslings were primed intramuscularly (i.m.) with high (75 µg) or low (15 µg) doses GoCVsubvac, followed by a boost 14 days later. At 14 days post-boost, goslings were challenged with GoCV and were administered a bivalent inactivated vaccine against Newcastle disease virus (NDV) and H9-subtype Avian influenza virus (AIV). Using our established gosling pathogenicity model, vaccine efficacy was evaluated via body weight, lesions, viral load, antibody titers, cytokine responses, and interference with NDV/AIV immunity. Results demonstrated that the GoCV-ΔCap vaccine, especially the high-dose formulation, provided effective immunoprotection. It elicited robust humoral and cellular immune responses, reduced lymphoid pathology, and decreased the viral detection rate in lymphoid tissues from 100% (5/5) in infected controls to 40% (2/5). Importantly, it alleviated GoCV-induced immunosuppression and preserved the immunogenicity of co-administered vaccines. This novel subunit vaccine is a promising candidate for controlling GoCV disease (GoCVD). Full article

Background/Objectives: HXP-GPOVac is a locally produced, inactivated Newcastle disease virus-based (NDV-HXP-S) COVID-19 vaccine manufactured in Thailand. This phase II trial compared its safety and immunogenicity with the mRNA vaccine BNT162b2 in adults aged 18–75 years. Methods: In this randomized, double-blind, active-controlled trial registered with the Thai Clinical Trials Registry (TCTR20220819003), 300 participants were assigned 3:1 to receive HXP-GPOVac or BNT162b2 on Days 1 and 29. Solicited adverse events (AEs) were recorded for 7 days after each dose, AEs were summarized through 28 days after each dose, and serious adverse events (SAEs), medically attended AEs (MAAEs), and adverse events of special interest (AESIs) were collected through Day 197. Humoral immunogenicity was assessed by pseudovirus 50% neutralization titers (NT₅₀) and anti-spike IgG concentrations at baseline, Day 29, Day 43, and Day 197. Seroconversion was defined as a ≥4-fold increase from baseline. A predefined subset underwent interferon-γ (IFN-γ) and interleukin-5 (IL-5) ELISpot assays to assess cell-mediated immune responses. The primary immunogenicity analysis assessed non-inferiority of HXP-GPOVac compared with BNT162b2 based on the NT₅₀ geometric mean titer ratio, with a prespecified non-inferiority margin of 0.5. Results: Solicited AEs were predominantly mild and occurred more frequently after the first dose in both groups; one or more solicited local or systemic AEs were reported by 23.7% (95% CI: 18.3–29.8) of HXP-GPOVac recipients and 44.7% (95% CI: 33.3–56.6) of BNT162b2 recipients after the first dose. AEs through 28 days after vaccination and SAEs were uncommon; MAAEs occurred in 17.0% of HXP-GPOVac recipients and 22.4% of BNT162b2 recipients, and none were considered related to vaccination. In the HXP-GPOVac group, NT₅₀ geometric mean titers increased from 5.6 at baseline to 65.5 at Day 29 and 505 at Day 43, declining to 63.6 at Day 197. Anti-spike IgG geometric mean concentrations rose from 7.5 BAU/mL at baseline to 102.7 BAU/mL at Day 29 and 514.6 BAU/mL at Day 43, decreasing to 61.0 BAU/mL at Day 197. BNT162b2 induced higher antibody levels at all time points. The NT₅₀ GMT ratio (HXP-GPOVac/BNT162b2) at Day 43 was 0.51 (95% CI: 0.39–0.67); the lower bound did not exceed the prespecified non-inferiority margin of 0.5, and non-inferiority was not established. Seroconversion rates at Day 43 were 97.6% for HXP-GPOVac and 97.1% for BNT162b2 (neutralizing antibody) and 98.6% and 97.1%, respectively (anti-spike IgG). ELISpot analyses demonstrated increased IFN-γ responses after the second dose without evidence of Th2-dominant skewing. Conclusions: HXP-GPOVac was well tolerated and induced substantial humoral and cellular immune responses, with high seroconversion rates and balanced T-cell polarization. Although absolute antibody levels were lower than those induced by BNT162b2 and the prespecified non-inferiority criterion was not met, these findings support continued evaluation of the inactivated NDV-HXP-S vaccine platform. Full article

Avian orthoavulavirus 1 (AOaV-1), commonly known as Newcastle disease virus (NDV), despite widespread vaccination, remains a significant threat to domestic chickens (Gallus gallus domesticus). Currently available live-attenuated NDV vaccines are derived from genotypes I and II lentogenic strains, whereas genetically divergent velogenic strains predominantly caused recent NDV outbreaks. This study examined the extent of genotypic divergence between NDV vaccine strains and field strains using phylogenetic and multivariate analyses of two major antigenic and virulence-associated genes: fusion (F) and haemagglutinin-neuraminidase (HN). A total of 121 full-length NDV-F and 81 NDV-HN gene sequences, representing reported NDV genotypes, were downloaded from GenBank and analysed using maximum-likelihood (ML) phylogenetic trees and principal coordinates analysis (PCoA). The phylogeny revealed genotype-specific clustering for both genes, consistent with current NDV classification. NDV vaccine strains belonging to genotypes I and II formed distinct clades, segregated from the majority of NDV field strains, including velogenic or virulent NDV genotypes. The principal coordinates analysis of both genes further confirmed the phylogenetic clustering of NDV genotypes, indicating increased genomic heterogeneity. These findings suggest genetic segregation of divergent velogenic or virulent genotypes from lentogenic NDV vaccines, requiring biological experiments for determining their efficacy against field strains. This study highlights the importance of molecular surveillance of NDV to monitor its genomic diversity, which is crucial for developing strategies to combat NDV outbreaks in domestic chickens. This study provides an updated, NDV-glycoprotein-gene-based comparative analysis across reported NDV genotypes using phylogenetic and multivariate approaches. Full article

Vaccination remains the core strategy for the prevention and control of Newcastle disease (ND). The inherent thermosensitivity of traditional Newcastle disease virus (NDV) vaccines imposes major limitations on their transportation, storage, and field application. To address these challenges, a novel liquid, thermostable, live ND vaccine was developed in the present study. Firstly, Tris/HCl buffer at near-neutral pH was identified as the optimal basic buffer system. On this basis, further screening and formulation optimization of vaccine stabilizers were conducted, and NDV strains with excellent thermal stability were used to verify the stability-conferring properties of the developed stabilizer. The results showed that the formulation composed of 0.5% gelatin, 4% trehalose, 0.1% L-glutamic acid, and 0.5% thiourea was confirmed as the optimal stabilizer for ND liquid vaccines. This formulation maintained the stable storage of the tested NDV for 12 months at 4 °C and exhibited promising stability for 30 days at 25 °C, marking a significant advancement toward development thermostable NDV vaccines that are independent of a continuous cold chain. More importantly, the liquid vaccine stored at 4 °C for 12 months still induced high levels of NDV-specific antibodies in specific pathogen-free chicks and provided 100% protective efficacy against challenge with virulent NDV. In conclusion, the liquid vaccine stabilizer developed in this study not only significantly enhanced the thermostability of the vaccine but also effectively maintained its immunogenicity, thereby providing an important theoretical basis for the research and development of liquid ND vaccines. Full article

Pigeon Newcastle disease poses a persistent threat to the global pigeon industry, underscoring the need for effective vaccination strategies. While both inactivated and DNA vaccines offer distinct advantages, the immunogenicity of a combined heterologous regimen remains underexplored. This study evaluated and compared three immunization strategies in pigeons: a DNA vaccine encoding the NDV F protein fused with chicken IL-18, an inactivated vaccine from a local virulent strain, and a DNA prime-inactivated boost regimen. The preparation workflows for both vaccine platforms are described in detail to provide methodological context for the immunological comparison. Critically, the prime–boost regimen elicited significantly higher hemagglutination inhibition (HI) antibody titers than either vaccine administered alone, demonstrating a clear synergistic effect. These findings highlight the complementary roles of the two platforms and provide a strong immunological rationale for further evaluation of this sequential strategy. Future studies incorporating viral challenge experiments and long-term immune monitoring are needed to determine whether the enhanced HI antibody response translates into protective efficacy under field conditions. Full article

Background/Objectives: Combined vaccination against avian influenza (A/H5N3, A/H7N7) and Newcastle disease is of practical interest for reducing handling during immunization and for achieving timely protection in poultry. The aim of this study was to evaluate an inactivated combined (associated) vaccine containing antigenic variants of avian influenza viruses A/H5N3 and A/H7N7 and Newcastle disease virus (NDV). The vaccine is protected by Patent No. 87417. Methods: Viruses with initial reproductive titers of 10^7.5 EID₅₀/mL were inactivated with formaldehyde and formulated as mono-, bi-, or trivalent combinations. Antigens were adsorbed onto aluminum hydroxide gel (1.5%). Immunogenicity was assessed in chicks naïve to avian influenza and Newcastle disease using hemagglutination inhibition (HI) antibody kinetics. Vaccination was performed twice with a 21-day interval. Group administration via drinking water (5 mL/bird) was compared with parenteral administration (1.0 mL/bird). Protective efficacy was evaluated by challenge with virulent viruses at day 30. Sterility and safety/reactogenicity were assessed, and immunobiological performance was additionally evaluated under household farm conditions (337 chickens). Results: Following vaccination, protective immunity was observed starting from day 14. HI titers peaked by day 30 (7.6–7.8 log₂ for A/H5N3 and A/H7N7; 9.2 log₂ for NDV) and remained detectable through 180 days (4.3–4.7 log₂ for avian influenza antigens; 5.1 log₂ for NDV). Group administration via drinking water produced antibody kinetics comparable to parenteral vaccination, and vaccinated birds were resistant to challenge at day 30. The tested batches met sterility requirements and showed acceptable safety/reactogenicity in laboratory studies. Conclusions: The developed inactivated combined vaccine induced HI antibodies and protective immunity against avian influenza (A/H5N3, A/H7N7) and Newcastle disease. The formulation concept supports flexible antigen combinations and enables group administration via drinking water, which may reduce handling compared with separate vaccinations. Full article

Background/Objectives: We previously developed a low-cost vaccine based on Newcastle disease virus expressing a stabilized pre-fusion spike of SARS-CoV-2 (NDV-HXP-S), which has shown safety and immunogenicity in pre-clinical and clinical studies. Due to the emergence of immune-evasive variants and the need to protect vulnerable populations, we evaluated adjuvanted NDV-HXP-S vaccine formulations to enhance and broaden immune responses. Methods: We tested the antibody responses of mice immunized intramuscularly with an inactivated NDV-HXP-S vaccine adjuvanted with AddaVax, AddaS03, Alhydrogel adjuvant 2% (Alum), or Quil-A. Results: AddaVax, AddaS03, and Alum induced the strongest IgG responses to the ancestral spike protein, boosted cross-reactive antibodies against both S1 and S2 subunits, and elicited high cross-neutralizing titers. Conclusions: The present results highlight the critical role of adjuvant selection in shaping both the magnitude and breadth of the immune response induced by the NDV-HXP-S vaccine. AddaVax, AddaS03, and Alum stand out as promising candidates to enhance NDV-HXP-S vaccine immunogenicity, with potential applications in booster strategies against SARS-CoV-2, enabling dose sparing and reducing costs. Full article

Background/Objective: The poultry industry requires extensive vaccination of chickens against IBV in an effort to prevent the disease in animals and significant economic losses. Current vaccination strategies often lack effectiveness, and the continual emergence of new IBV variants makes disease control increasingly challenging. We have developed an inactivated vaccine for poultry containing nine different antigens (Nobilis Multriva), including two IBDV strains, two ARV strains, one NDV strain, one AMPV strain, one EDSV strain and two IBV strains: M41 (genotype GI-1) and 4–91 (genotype GI-13). In this study, the IB efficacy of this novel inactivated vaccine was investigated against homologous and heterologous IBV strains. Methods: Inactivated IBV vaccine containing the M41 and 4–91 strains (Nobilis Multriva) was administered intramuscularly, either alone or following vaccine priming, in SPF and commercial chickens. Birds were challenged with homologous and heterologous IBV strains at defined ages (peak of lay, mid-lay and end of lay). Vaccine efficacy was evaluated through serological assays, clinical observations, and monitoring of egg production post-challenge. Results: This vaccine provided excellent broad protection against different IBV strains circulating in different parts of the world, including IBV M41, 4–91, QX, Q1 and Var2. Furthermore, the vaccine provided long-lasting IBV serological response against IB M41 and IB 4–91 until at least 96 weeks of age in SPF and commercial layers and breeder birds. This vaccine will allow farmers to reduce the number of vaccination moments, thereby minimizing stress to the birds, while also decreasing labor demands and the risk of human error, ultimately contributing to lower overall vaccination costs. Conclusions: Given its demonstrated broad cross-protection and sustained serological responses, this nine-valent inactivated vaccine (Nobilis Multriva) represents a key component of an effective vaccination regimen for controlling IBV infections in the poultry industry. Full article

Genotype VII Newcastle disease virus (NDV) has been confirmed as the predominant epidemic strain in China. Traditional vaccine strains fail to provide complete immune protection when challenged with an epidemic strain. NDV vaccines with phylogenetic relationships closer to those of the endemic viruses demonstrate improved protective efficacy in reducing viral shedding and transmission. This research seeks to develop attenuated vaccine strains that are specifically aligned with NDV genotype VII. A reverse genetics system for the genotype VII NDV HB strain was developed, successfully rescuing the attenuated recombinant virus aHB by substituting the fusion protein (F) cleavage site motif “¹¹²R-R-Q-K-R↓F¹¹⁷” with “¹¹²G-R-Q-G-R↓L¹¹⁷.” Recombinant aHB virus attenuation was verified by assessing the mean death time (MDT) and intracerebral pathogenicity index (ICPI). The attenuated aHB strain demonstrated greater proliferation titers than did the virulent HB and rHB strains both in vivo and in vitro. Furthermore, the genome exhibited significant genetic stability even after 10 passages in chicken embryos. When challenged with the HB strain of NDV genotype VII, the aHB-inactivated vaccine provided 100% protection to chickens and effectively prevented viral shedding. These findings indicate that recombinant aHB may serve as an effective vaccine candidate. Full article

The diseases caused by genotype VII Newcastle disease virus (NDV), H9N2 avian influenza virus (AIV), and fowl adenovirus serotype 4 (FAdV-4) continue to threaten the global poultry industry. However, no broad-spectrum vaccines provide simultaneous protection against these three pathogens. This study employed bioinformatics and immunoinformatics approaches to design a multi-epitope vaccine, named NFAF, which consists of B-cell, cytotoxic T lymphocyte (CTL) epitopes, and helper T lymphocyte (HTL) epitopes derived from hemagglutinin-neuraminidase (HN) and fusion (F) proteins of genotype VII NDV, hemagglutinin (HA) protein of H9N2, and Fiber2 protein of FAdV-4. The vaccine candidate was predicted to have non-allergenic properties, non-toxicity, high antigenicity, and favorable solubility. Each of its constituent antigenic epitopes has a high degree of conservation. Molecular docking demonstrated stable binding between NFAF and chicken Toll-like receptor (TLRs) and major histocompatibility complex (MHC) molecules. NFAF was expressed in soluble form in Escherichia coli and purified. Polyclonal antibodies against all three target viruses showed specific binding to NFAF. In vitro experiments revealed that NFAF effectively stimulated chicken peripheral blood mononuclear cells (PBMCs) and induced Th1, Th2, and pro-inflammatory cytokine production, confirming its immunogenicity, and increased the mRNA expression of the key signaling molecules MyD88 and NF-κB. These results suggested that NFAF could therefore be an efficacious multi-epitope vaccine against genotype VII NDV, H9N2, and FAdV-4 infections. Full article

The rapid emergence and evolution of avian viral pathogens present a major challenge to global poultry health and food security. Traditional vaccine development is often slow, costly, and limited by antigenic diversity. In this study, we present a comprehensive artificial intelligence (AI)-driven pipeline for the rational design, modeling, and optimization of multi-epitope vaccines targeting economically important RNA and DNA viruses affecting poultry, including H5N1, NDV, IBV, IBDV, CAV, and FPV. We utilized advanced machine learning and deep learning tools for epitope prediction, antigenicity assessment, and structural modeling (via AlphaFold2), and codon optimization. B-cell and T-cell epitopes were selected based on binding affinity, conservation, and immunogenicity, while adjuvants and linker sequences enhanced construct stability and immune response. In silico immune simulations forecasted robust humoral and cellular responses, including cytokine production and memory cell activation. The study also highlights challenges such as data quality, model interpretability, and ethical considerations. Our work demonstrates the transformative potential of AI in veterinary vaccinology and offers a scalable model for rapid, data-driven vaccine development against avian diseases. Full article

The Newcastle disease virus (NDV), an avian paramyxovirus, induces the highly contagious Newcastle disease in poultry. Newcastle disease outbreaks, common in many developing countries, have been recorded worldwide for a century. Poultry, even vaccinated stocks, together with wild and synanthropic birds, serve as reservoirs of NDV. Despite the extensive use of commercial NDV vaccines, Newcastle disease outbreaks frequently occur in vaccinated chickens, resulting in great economic losses. The primary limitation of commercial Newcastle disease vaccines is their restricted compatibility with emerging novel NDV strains. The advancement of vaccines and vaccination techniques is anticipated to reduce the propagation of pathogenic NDV strains and consequently alleviate losses in poultry production. This review examines the NDV genotypes and strains implicated in both current and historical Newcastle disease outbreaks, and evaluates existing and candidate NDV vaccines, emphasizing recent innovations and novel techniques. Our aim was to delineate critical subjects for future inquiry and to furnish extensive data that could aid researchers in understanding the current advancements and existing problems in Newcastle disease vaccination prophylactics. The emergence of a new generation of vaccines employing advanced technologies may substantially improve the efficacy of Newcastle disease prevention and control. Full article

Newcastle disease (ND) is a highly contagious and economically significant viral infection that affects poultry globally, with recurrent outbreaks occurring even among vaccinated flocks in Egypt. Caused by the Newcastle disease virus (NDV), the disease results in substantial losses due to high mortality rates, decreased productivity, and the imposition of trade restrictions. This study aimed to develop a rapid, sensitive, and field-deployable diagnostic assay based on real-time reverse transcription recombinase-aided amplification (RT-RAA) for the detection of all NDV genotypes in clinical avian specimens. Primers and an exo-probe were designed based on the most conserved region of the NDV matrix gene. After testing ten primer combinations, the pair NDV RAA-F1 and RAA-R5 demonstrated the highest sensitivity, detecting as low as 6.89 EID₅₀/mL (95% CI). The RT-RAA assay showed excellent clinical sensitivity and specificity, with no cross-reactivity to other common respiratory pathogens such as avian influenza virus, infectious bronchitis virus, Mycoplasma gallisepticum or infectious laryngotracheitis virus. All 25 field samples that were tested positive by real-time RT-PCR, including those with high CT values (~35), were detected by RT-RAA in 2–11 min, indicating superior sensitivity and speed. The assay requires only basic equipment and can be performed under isothermal conditions, making it highly suitable for on-site detection in resource-limited or rural settings. The successful implementation of RT-RAA can improve NDV outbreak response, support timely vaccination strategies, and enhance disease control efforts. Overall, the assay presents a promising alternative to conventional diagnostic methods, contributing to the sustainability and productivity of the poultry sector in endemic regions. Full article

Newcastle Disease (ND) is an important and notable disease among the avian infectious diseases, because of its high contagiousness, and the most virulent strains of ND virus (NDV) have impacted poultry breeders all over the world. Immunization and biosecurity measures are used to reduce ND; however, vaccination has been shown to offer protection against clinical signs but not against virus proliferation and shedding, which could have an adverse effect on the environment. The genetic basis for inherent resistance to NDV has been established, and genetic selection on existing resistance-related genetic variation can help to mitigate virus propagation. Further, understanding the genes and processes that drive the response to NDV will lay the groundwork for genetic improvement in poultry. The majority of studies on NDV susceptibility make use of phenotypic indicators such as body weight, morbidity, mortality, antibody response, and viral load. According to recent advancements in molecular genetic research, many different genes are diversely regulated in different chicken lines to NDV infection, which might be used in the future to establish disease-resistant breeding approaches. It is possible that many more genes linked to illness and resistance are still to be discovered, because the precise mechanism of resistance is not entirely understood. The enhanced genetic knowledge of chickens and the development of more advanced transgenic techniques would lead to pathogen resistance. Hence, this paper summarizes the current understanding of genetic resistance to Newcastle Disease, and we additionally highlight a few possible genes/markers connected with NDV that may improve chicken resistance to NDV infections and can be used to produce NDV-resistant chicken breeds/strains in the near future. Full article

To determine if exposing embryos to light during incubation affects antibody titer and corticosterone immediately following hatch, we incubated layer eggs and exposed them to light or darkness and vaccinated a subset of each treatment against Newcastle Disease Virus (NDV) using in ovo administration on ED 18, spray application at hatch (d 0), or not at all. There were six treatments: light incubated and non-vaccinated (LNV), light incubated and in ovo vaccinated (LIV), light incubated and post-hatch vaccinated (LPHV), dark incubated and non-vaccinated (DNV), dark incubated and in ovo-vaccinated (DIV), and dark incubated and post-hatch vaccinated (DPHV). Plasma corticosterone (CORT) and NDV antibody titers were measured on d 0, 7, and 14. Light-incubated chicks had lower (p < 0.05) plasma CORT on d 0. NDV titers did not differ (p > 0.05) between light- and dark-incubated chicks on d 0, 7, or 14. However, LIV chicks had higher antibody titers than LPHV on d 14. Exposing embryos to continuous green light during incubation may reduce stress during the early post-hatch period. Vaccination method, rather than exposure to continuous green light during incubation, may have a greater impact on humoral immune response post-hatch. Full article